This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



netarsudil mesylate (Rhokiinsa®)


Reference No. 3751

Publication date:
16/06/2020


Appraisal information

netarsudil mesylate (Rhokiinsa®) 200 microgram/ml eye drop solution


Company: Aerie Pharmaceuticals
BNF category: Eye
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, netarsudil mesylate (Rhokiinsa®) cannot be endorsed for use within NHS Wales for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension
Statement of Advice (SOA)
Download